Dear friend,
The Council of Canadians is calling on the federal government and the Patented Medicines Price Review Board (PMPRB) to immediately launch an inquiry into the high price of Synagis, a drug that prevents RSV in at-risk infants.
TAKE ACTION NOWSynagis, produced by the pharmaceutical company AbbVie, currently costs between $5,000 and $9,000 per child, per RSV season. A cost that in its 24-years on the market has never went down and is a mark-up that is 27 times more than the cost of producing the medicine.
This prohibitive expense has led public health authorities to restrict access to the treatment.
The children most impacted by the lack of access to this essential medicine are Inuit infants living in the Arctic. These children tend to get much sicker with RSV, often experiencing associated bronchiolitis, pneumonia, and in some cases, even death. It is not uncommon for Inuit children to require medivac by helicopter from their home communities to better-equipped hospitals in the south.
The drug's high price tag doesn't reflect the cost of making it – it reflects the greed of the company that produces it. This is why we are asking you to take action today.
READ MORECanada must investigate why Big Pharma price gouging is keeping life-saving medicine from kids.
Contact Minister for Health Jean-Yves Duclos, Prime Minister Justin Trudeau, and your MP and urge the federal government to take action now.
CONTACT YOUR MP